Table 4

Activity and efficacy according to KRAS genotype (intent-to-treat analysis)

ORR (%)

PFS (m)

range

OS (m)

range


KRAS wild-type plus other than c.35 G>A KRAS mutant (44 pts)

81 (CI ± 12)

13

34

1+-69+

1+-69+

KRAS wild-type (30 pts)

90 (CI ± 11)

14

38

1+-69+

1+-69+

KRAS wild-type/BRAF wild-type (18 pts)

83 (CI ± 14)

13

31

4-44

8-66+

other than c.35 G>A KRAS mutant (13 pts)

61 (CI ± 30)

12

39

3-37

8-59+

c.35 G>A KRAS mutant (14 pts)

71 (CI ± 26)

9

14

1+-60+

1+-60+

c.35 G>T KRAS mutant (7 pts)

57 (CI ± 40)

12

21

3-25

11-46+


m, months; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.

Bruera et al. BMC Medicine 2013 11:59   doi:10.1186/1741-7015-11-59

Open Data